Extract

Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to IFX. Papadakis KA, Shaye OA, Vasiliauskas EA, et al. Am J Gastroenterol. 2005;100:75-79.

Some patients with Crohn's disease (CD) who respond to infliximab (IFX) eventually lose their response and require alternate therapies. Papadakis et al from Cedars Sinai studied retrospectively 15 patients with active CD who had experienced an attenuated response to IFX and who subsequently received adalimumab. The treating physicians determined the development of an attenuated response to IFX, which was defined as an increase of IFX dosage to 10 mg/kg every 8 weeks without maintaining clinical response. Patients considered for adalimumab had moderately to severely active disease, steroid dependence, failure of standard immunomodulators, and/or draining fistulae. Patients received adalimumab 80 mg subcutaneously at week 0 and continued on 40 mg every 2 weeks. Disease activity was measured using the Harvey-Bradshaw index (HBI). Complete response (CR) was defined as an HBI of no more than 4 and withdrawal of corticosteroid treatment. Partial response (PR) was defined as a decrease of at least 50% in HBI and a decrease in corticosteroid dose.

You do not currently have access to this article.